The COVID-19 pandemic posed a significant challenge for clinicians in managing pregnant
women, who were at high risk of virus transmission and severe illness. While the WHO …

Objectives We describe clinical characteristics, pregnancy, and infant outcomes in pregnant
people with laboratory‐confirmed SARS‐CoV‐2 infection by trimester of infection. Study …

Background Nirmatrelvir, in combination with ritonavir, is one of the first orally available
antiviral treatment for coronavirus disease 2019 (COVID‐19). Symptomatic pregnant women …

Although pregnant women were considered a risk population for COVID-19, little is known of
their drug use during the pandemic. We aimed to investigate COVID-19 distribution, drug …

There is limited evidence about the use of medications among pregnant women with COVID‐
19, as well as risk factors for hospitalization due to COVID‐19 in pregnancy. We aimed to …

Purpose The COVID-19 pandemic has impacted medication needs and prescribing
practices, including those affecting pregnant women. Our goal was to investigate patterns of …

2. METHOD Placentas were obtained from women who delivered at Port Royal maternity,
Paris, France. All patients received an information note and gave a written consent for this …

Background There is a dearth of drug utilization studies for coronavirus disease 2019
(COVID-19) treatments in 2021 and beyond after the introduction of vaccines and updated …

Background: Prescribing pattern in pregnancy population provide insights during drug
profile and also minimizes the inherent risks due to unethical prescribing. The study aimed …

Background: The coronavirus disease 2019 (COVID-19) can have a variety of effects on
pregnant women, from mild symptoms to severe complications. Those with underlying …